Drug · DIN 02422956
ALPROLIX
KIT CONTAINING A) SINGLE-USE VIAL AND B) DILUENT (5 ML PREFILLED SYRINGE)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 22, 2021; first marketed January 15, 2016.
- Drug Identification Number (DIN)
- 02422956
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Kit; Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor ix B02BD04
- Class
- Human
- Record last updated
- September 21, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN | 3000 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 17, 2017: NOC 19311New Drug Submission (NDS) · Merger - buyout
- March 20, 2014: NOC 15435New Drug Submission (NDS)
Other DINs named ALPROLIX
- DIN 02422913 · Marketed
- DIN 02422921 · Marketed
- DIN 02422948 · Marketed
- DIN 02422905 · Approved
- DIN 02474034 · Approved